Am. J. Transpl 2003 3:665. 1969 Immediate failure Kidney recipients Patel, Terasaki, N Engl J Med 280:735, 1969 with antibodies, pos XM 24/30.

Slides:



Advertisements
Similar presentations
Immunology of Renal Transplant
Advertisements

Terasaki Festschrift 2014 Clinical Relevance of Pre- and Post-Transplant HLA antibodies, Donor-Specific and Non-Donor-Specific HLA Antibodies Detected.
PRA = 36% (21/58) Anti-A11 and B44.
Acceptable mismatches based on structural epitopes on HLA molecules Toulouse, April 2, 2008.
Complement in Heart Allograft Biopsies E. Rene Rodriguez W. M. Baldwin, III.
Michael Mengel Department of Laboratory Medicine and Pathology
Lysaght, J Am Soc Nephrol, 2002 Number of patients worldwide treated with chronic dialysis from 1990 to ,000 1,490,000 2,500,000.
Cells, tissues and organs All living organisms are made up of cells. Large numbers of cells group together to form tissue. Tissues can combine to form.
Effects of Humoral Antibodies in Organ Transplantation: Boon or Bane? Reference: Ponticelli C. Humoral antibodies in organ transplantation: Angels or demons?
Transplantation Autologous Syngeneic Allogeneic Xenogeneic.
30-Year Retrospective on Organ Transplant Immunosuppression in the Era of Calcineurin Inhibitors Herwig-Ulf Meier-Kriesche, MD Professor of Medicine Department.
CHAPTER 3 HEART AND LUNG TRANSPLANTATION Editors: Mr Mohamed Ezani Md. Taib Dato’ Dr David Chew Soon Ping Dr Ashari Yunus Expert Panel: Mr Mohamed Ezani.
The Significance of C4d Staining with Minimal Histologic Abnormalities
HLA Ab, Donor Reactivity and Risk of Rejection and Graft Loss HLA Ab, Donor Reactivity and Risk of Rejection and Graft Loss Ronald H. Kerman, PhD The University.
RENAL TRANSPLANTATION INTO HIGH RISK, HIGHLY SENSITIZED RECIPIENTS: A SINGLE CENTER EXPERIENCE Randy Hennigar PhD, MD Director, Nephropathology and Electron.
Jeremy Chapman Westmead Hospital, Sydney CMV Infection and Allograft Rejection : Are we missing the point?
… Rejection Transplantation Biology:. Kidney rejection:
The European experience with protocol biopsies Ian Roberts Oxford, UK Oxford Pathology.
Living Donor Kidney Transplant. What does the evidence say about outcome ? Professor Peter J Conlon.
ANZDATA Registry Annual Report 2013 CANCER CHAPTER 10.
ERYTHROCYTE C4d: A MARKER OF ANTIBODY MEDIATED REJECTION
BWGHF Liège Heart transplantation 2008.
Tolerance Induction after Kidney Transplantation Stephan Busque MD M Sc FRCSC Director, Adult Kidney and Pancreas Transplantation Program Stanford University.
Monitoring HLA-specific antibodies
1 Influence of donor & recipient risk factors and the choice of immunosuppression Long term outcome after renal transplantation Influence of donor & recipient.
TRANSPLANTATION & REJECTION Objectives: Upon the completion of this lecture the students are expected to: Know the benefits of transplantation in clinical.
Hepatitis C+ Recipients: Considerations for Exclusion Emily A. Blumberg, M.D.
Study of cytokine gene polymorphism and graft outcome in live-donor kidney transplantation By Rashad Hassan MD Amgad El-Agroudy, Ahmad Hamdy, Amani Mostafa.
Interactive Case Discussion Case 6 Dr Megha S Uppin Asst Prof Dept of Pathology Nizam’s Institute of Medical Sciences Hyderabad.
Kidney transplant case Niels Marcussen Hans Dieperink Odense University Hospital.
Humoral rejection: What the pathologist needs to know Humoral rejection: What the pathologist needs to know Heinz Regele Heinz Regele Clinical Institute.
TRANSPLANTATION CHAPTER 8 ANZDATA Registry Annual Report 2013.
RAPAMUNE ® TM 1 Randomization Variable Day* to Day 386 Randomization Variable Day* to Day 386 RAPA, C min, TN0.765 CsA, C min, TN0.201 Gender0.117 Increasing.
Prognostic significance of C4-positive vs. negative rejection Heinz Regele Heinz Regele Department of Pathology Innsbruck Medical University Heinz Regele.
Immunology of transplantation. Types of transplantation Autotransplantation –within one organism Allotransplantation- between one species Xenotransplantation-
Single HLA Antigen Bead Data Interpretation: Normalized Ratios Peter Stastny Transplantation Immunology Division Departments of Internal Medicine and Pathology.
© 2014 Direct One Communications, Inc. All rights reserved. 1 How to Maximize Outcomes and Minimize Graft Failure Thin Thin Maw, MBBS Washington University.
 What I Already Knew. What I Already Knew.  My Search Results. My Search Results.  What I Learned. What I Learned.
C4d in pancreas transplant biopsies: the Leiden experience Ingeborg Bajema Ingeborg Bajema Ingeborg Bajema.
Successful Multivisceral plus Kidney Transplantation of a highly sensitised paediatric recipient; with Eculizumab salvage for hyperacute renal rejection.
TRANSPLANTATION & tissue rejection
Histological markers of CNI nephrotoxicity: Specific or not specific? Marion Rabant MD, Renaud Snanoudj MD, Virginie Royal MD, C. Girardin, E.Morelon MD.
Transplantation of Tissues and Organs
”Insight into the role of non-HLA antibodies and Rejections”
AbSorber  Rejection & Graft Survival  XM-ONE ®.
D. Serón Nephrology Department Hospital Vall d’Hebron Barcelona Interpretation of sequential protocol biopsies in terms of prognosis and clinical implications.
Reference: Gloor J, Stegall MD
Management of sensitized patients in kidney transplantation.
Draft Organ Allocation Criteria. Factors affecting Allocation Medical need Length of waiting time: time a illness progressed to a point when transplant.
United States Organ Transplantation SRTR & OPTN Annual Data Report, 2011 Kidney.
Donor Matching of Kidney Transplantation
THE AUSTRALIA AND NEW ZEALAND CARDIOTHORACIC ORGAN TRANSPLANT REGISTRY
Pre-transplant soluble CD30 (sCD30) for the prediction
Graft Dysfunction after Heart Transplantation
Evan P. Kransdorf, MD, PhD, Michelle M. Kittleson, MD, PhD, Jignesh K
Hong Kong Workshop Lecture 8 HLA Epitopes and Acceptable Mismatches for Sensitized Transplant Patients.
Table 3.1.1a: Stock and Flow of Heart Transplantation,
Anand Yuvaraj International Transplant Fellow
Number of Grafts Performed by Country
FIGURE 1 Trial profile. The safety population was defined as all randomly assigned patients who received at least one dose of study drug. All patients.
Transplantation Pathology
C. Chalklin, C. Colmont, A. Zaidi, J. Warden-Smith, E. Ablorsu
Kidney allocation to highly sensitized patients
Transplant Immunology
Volume 79, Issue 6, Pages (March 2011)
Transplantation Immunology
ANZDATA Registry Annual Report 2013
Transplantation Immunology
Overcoming Barriers to Long-Term Graft Survival
Presentation transcript:

Am. J. Transpl :665

1969 Immediate failure Kidney recipients Patel, Terasaki, N Engl J Med 280:735, 1969 with antibodies, pos XM 24/30

Percent Cause of death Primary Graft Failure Hyperacute Rejection

Hyperacute Rejection Percent of Hyperacute % PRATransplant No < >8012>

Primary Non-function < >8012>2 % PRATransplant No. Percent of Primary Nonfunction

Graft Failure in 1 month % PRA Transplant No. Percent of Graft Failure < >8012>

Feucht, Albert, et al. Kidney Intern 43: , 1993 C4d- (N =42) C4d+ (N =43) Months Posttransplant Graft Survival (%) 90% 57% Biopsies within first month

Lederer, et al. Kidney International 59: , C4d- (N =101) C4d+ (N =117) Years Posttransplant Cumulative Survival (%) P=

Feucht, Schneeberger, et al. Kidney Int 1993: 43:1333. Lederer, Kluth-Pepper, et al. Kidney Int 2001; 59:334. Feucht, Opelz. Kidney Int 1996: 50:1464. Behr, Feucht, et al. J Heart Lung Transplant 1999; 18:904. C4d publications

Crespo, Pascual, et al. Transplantation 2001; 71:652. Mauiyyedi, Pelle, et al. J Am Soc Nephrol 2001; 12:574. Mauiyyedi, Colvin. Curr Opin Nephrol Hypertens 2002; 11:609. Mauiyyedi, Crespo, et al. J Am Soc Nephrol 2002; 13:779. Collins, Schneeberger, et al. J Am Soc Nephrol 1999; 10:2208.

Regele, Watschinger, et al. Nephrol Dial Transplant 2001; 16:2058. Bohmig, Exner, et al. J Am Soc Nephrol 2002; 13:1091. Bohmig, Exner, et al. Curr Opin Urol 2002; 12:95. Watschinger, Pascual. J Am Soc Nephrol 2002; 13:2420. Nickeleit, Zeiler, et al. J Am Soc Nephrol 2002; 13:242.

Review: Anti-HLA antibodies post transplant in solid organ transplantation McKenna, Takemoto, Terasaki Transplantation 69:319, 2000 American J Transplantation, June, 2003

El Fettouh, Cook, et al. Urology 2000; 56:369. Muller-Steinhardt, Fricke, et al. Clin Transplant 2000; 14:85. Kerman, Katz, et al. Transplant Proc 2001; 33:402. Worthington, Martin, et al. Transpl Proc 2001; 33:475. Tambur AR, Bray et al.Transplant 2000; 70:1055

Piazza, Poggi, et al. Transplantation 2001; 71:1106. Piazza, Borrelli, et al. Transpl Int 2000; 13:s439. Pelletier, Adams, et al. Am J Transplant 2002; 2:134. Palmer, Davis, et al. Transplantation 2002; 74:799. Lau, Palmer, et al. Ann Thorac Surg 2000; 69:1520. T

54% N= , Morris 72% N= , Iwaki 82% N= , Park N= , Harmer 95% After failure or removal of graft

54% N= , Morris 72% N= , Iwaki 82% N= , Park N= , Harmer 95% After failure or removal of graft

54% N= , Morris 72% N= , Iwaki 82% N= , Park N= , Harmer 95% After failure or removal of graft

54% N= , Morris 72% N= , Iwaki 82% N= , Park N= , Harmer 95% After failure or removal of graft

% ELISA AHG % Lazda N = 445 AHG 96% 33 N=825 at 5 centers 2001, El Awar AHG 152 Rosenberg, N = 254 El-Awar,Terasaki et al, Transpl Proc 34:2531, 2002 After failure or removal of graft

Time to antibody Time to failure 0<6M1yr yr Lee,Terasaki, Transpl 74:1192, 2002

Class II Years Posttransplant Time to antibody Time to failure Worthington, et al. Transplantation 2003, 75:1034

I Years Posttransplant Class I Time to antibody Time to failure Worthington, et al. Transplantation 2003, 75:1034

Renal allograft - Post transplant Chronic Rejection

To prove the role of HLA antibodies in a prospective trial, One year ago 2,551 patients with functioning transplants were tested for HLA antibodies

KIDNEY LUNG LIVER HEART 36 International transplant centers, patients tested in 2002 % HLA antibody Post-transplant

N CsA, Aza CsA, MMF FK, Aza FK, MMF < * Combination Drug No pre-tx antibody

Date of transplant in 2,551 patients 1 yr wait period Antibody 0203 No antibody

DirectorCountryTotalPositiveNegative Schonemann Germany 621 3/1055/516 Sada Japan 191 0/600/131 Semana France 159 2/81/151 Bow MA, USA 158 1/345/124 Neumann/ Michelon Brazil 156 1/202/136 Humar Croatia 151 4/351/116 Kidney Transplants

DirectorCountryTotalPositiveNegative LeforFL, USA 145 4/562/89 Piazza/ Adorno Italy 126 2/293/97 duToit/ Taljaard S.Africa 110 0/270/83 Milford/ Capenter MA, USA 107 2/326/75 McAlackPA, USA 79 1/146/65 JobimBrazil 78 0/80/70

DirectorCountryTotalPositiveNegative Slavcev Czech 71 1/302/41 Christiansen Australia 63 1/150/48 Polymenidis/ Skoura Greece 59 1/81/51 Stavropoulos- Giokas Greece 54 1/80/46 Mehra/ Panigrahi India 47 6/372/10 Zeevi PA, USA 42 1/131/29

DirectorCountryTotalPositiveNegative Crowe/Langon e TN, USA 30 0/81/22 Saidman MA, USA 24 0/40/20 Orosz/ Pelletier OH, USA 24 0/50/19 TaitAustralia 23 0/51/18 Fuggle Oxford, UK 21 1/41/17 Mahoney**/ Breggia MA, USA 9 0/20/7 Abdelnoor/ Shrayteh Lebanon 3 0/00/3

Deaths in a total 2551 patients followed one year 567 with antibody 1,984 without antibody 1 year later, 32 died 1.1% died 1.9% died P=0.08

Graft failure in a total 2551 patients followed one year 567 with antibody 1,984 without antibody 1 year later, 72 fail 2.0% fail 5.6% fail P=

Graft failure in patients without pre- transplant antibody 1,725 total 256 with antibody 1,469 without antibody 1 year later, 45 fail 1.9% fail 6.6% fail P=

The tests were done by PRA (panel reactive antibodies), but are Donor Specific antibodies found?

#11 Single antigen flow cytometry beads Produced by isolating antigens from recombinant lines, and adhering to beads Pei, Lee et al Transpl :43

#29 A1 A2 A3 A69 A66 A29 A30 Cont A26 B38 B57 B7 B52 B27 B8 B65 Cont B55 Single antigen beads

XX 10 9 XX 8 7 X X X ID Single Antigen A-Allele Typings Serum Antibodies in patients AFTER rejection Pei, Lee et al Transpl :43

XX 10 9 XX 8 7 X X X ID Single Antigen A-Allele Typings Serum Antibodies in patients AFTER rejection Pei, Lee et al Transpl :43

ID Single Antigen A-Allele Typings Serum 25 Berlin, Schonemann Recip Mism

HLA antibodies were found to predict chronic rejection in a prospective trial. They should therefore be useful in increasing or decreasing immunosuppression

Humoral Theory of Transplantation Am. J. Transpl :665 HLA antibodies cause : Hyperacute rejection Damage by early non function Acute rejection Chronic rejection

Humoral Theory of Transplantation Am. J. Transpl :665 HLA antibodies cause : Hyperacute rejection Damage by early non function Acute rejection Chronic rejection

Humoral Theory of Transplantation Am. J. Transpl :665 HLA antibodies cause : Hyperacute rejection Acute rejection

Humoral Theory of Transplantation Am. J. Transpl :665 HLA antibodies cause : Hyperacute rejection Acute rejection Chronic rejection

HLAtransplantationconference.org Los Angeles, Century Plaza Hotel Jan 31 to Feb 1, 2004